Orchestra BioMed Holdings, Inc. OBIO
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -14.81% | -431.32% | 129.98% | -7.57% | -3.24% |
| Total Depreciation and Amortization | 6.67% | 9.76% | 1.23% | 0.00% | -2.41% |
| Total Amortization of Deferred Charges | 1.56% | 0.00% | 8.47% | 28.26% | 0.00% |
| Total Other Non-Cash Items | 104.28% | -43.87% | 0.64% | 7.34% | 11.70% |
| Change in Net Operating Assets | 103.03% | 70.17% | -583.31% | 609.78% | 136.16% |
| Cash from Operations | 12.79% | -876.56% | 84.40% | 6.29% | 6.55% |
| Capital Expenditure | -38.04% | -457.58% | 89.35% | -811.76% | 69.64% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -319.53% | 159.40% | 53.81% | -333.52% | 25.01% |
| Cash from Investing | -325.91% | 158.25% | 54.09% | -335.90% | 25.83% |
| Total Debt Issued | -- | -- | -100.00% | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.86% | 281.14% | -97.33% | -- | -100.00% |
| Repurchase of Common Stock | 25.99% | 24.36% | -73.98% | 37.15% | -10.59% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 12.75% | -- | -- |
| Cash from Financing | 528.66% | -56.34% | -83.43% | 17,949.77% | -44.59% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -24.86% | 13.64% | -131.47% | 5,701.25% | 110.25% |